Ani Pharmaceuticals (ANIP) Total Current Liabilities (2010 - 2026)

Ani Pharmaceuticals has reported Total Current Liabilities for 17 years, with the latest figure at $239.5 million in Q1 2026.

• Quarterly Total Current Liabilities rose 18.68% year-over-year to $239.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $239.5 million (up 18.68% YoY) and the FY2025 annual result came in at $278.1 million, up 43.02% from the prior year.
• Total Current Liabilities eased to $239.5 million in Q1 2026 per ANIP's latest filing, from $278.1 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $278.1 million in Q4 2025 and troughed at $79.5 million in Q1 2022.
• A 5-year average of $163.1 million and a median of $140.0 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities retreated 3.91% in 2022, then jumped 69.19% in 2025.
• Over 5 years, Total Current Liabilities stood at $99.4 million in 2022, then surged by 46.3% to $145.5 million in 2023, then jumped by 33.67% to $194.5 million in 2024, then surged by 43.02% to $278.1 million in 2025, then slipped by 13.88% to $239.5 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $239.5 million, $278.1 million, and $270.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.